Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
NATIONAL INSTITUTES OF HEALTH has floated a tender for Next Generation Multipurpose Prevention Technologies (Ngm) (R01 Clinical Trial Optional). The project location is USA and the tender is closing on 07 Dec 2024. The tender notice number is PAR-22-222, while the TOT Ref Number is 69943985. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.
Procurement Summary
Country : USA
Summary : Next Generation Multipurpose Prevention Technologies (Ngm) (R01 Clinical Trial Optional)
Deadline : 07 Dec 2024
Other Information
Notice Type : Tender
TOT Ref.No.: 69943985
Document Ref. No. : PAR-22-222
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
Tender are invited for Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)
CFDA Number : 93.242 -- Mental Health Research Grants93.855 -- Allergy and Infectious Diseases Research93.865 -- Child Health and Human Development Extramural Research
Cost Sharing or Matching Requirement : No
Closing Date for Applications: Dec 07, 2024
Posted Date : Aug 04, 2022
Description: The objective of this Funding Opportunity Announcement (FOA) is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy; or multiple non-HIV STI or HIV/STI MPTs in cis and trans males and females of all ages. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development, and formulation science supported by animal model testing. Also supported are biobehavioral and behavioral/social studies to identify MPT user-desired rheological and biophysical factors (look, feel, effectiveness, safety, and duration of action) and other behavioral/social factors that could promote increased MPT adoption and use.
Documents
Want To Bid in This Tender?
Get Local Agent Support in USA and 60 More Countries.
View Tenders By
Sign in with Google